CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Candel Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.21+0.02 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $608.62M
- P/E (TTM)
- –
- Dividend yield
- –